Dr. Henry T. Tsai, MD

Dr. Tsai practices at Eisenhower Health in Rancho Mirage, California, part of Eisenhower Medical Center.

Dr. Tsai's NPI, 1659572261, was assigned on May 30, 2007. Dr. Tsai graduated from Wayne State University School Of Medicine in 2001. Dr. Tsai holds California license A99606.

Dr. Tsai's primary practice is Eisenhower Health, at 39-000 Bob Hope Drive, Rancho Mirage, CA 92270 in Riverside County. The practice phone is (760) 340-3911. Dr. Tsai also practices at Eisenhower Medical Center, 39000 Bob Hope Dr, Rancho Mirage, CA 92270.

Dr. Tsai's primary practice is Eisenhower Health in Rancho Mirage, California, part of Eisenhower Medical Center. Dr. Tsai is also affiliated with Loma Linda University Medical Center. The medical group on file is Eisenhower Health. Dmand AI also links Dr. Tsai to 1 more hospital, 2 home health agencies, 1 breast imaging center, 1 clinical lab and 1 dialysis center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tsai practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Tsai's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Tsai is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Tsai's licenses on file in 2 states: California and Georgia.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease and lung cancer among the conditions Dr. Tsai treats.

CMS data shows 3,591 Medicare services from Dr. Tsai across 9 procedure codes in 2024, for 1,245 Medicare patients. Medicare paid $304,117 for them.

CMS counts 1,245 Medicare patients who saw Dr. Tsai in 2024. The largest group is 75 to 84, with 540 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.98, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tsai's median patient age at 75, with 46% women.

In 2024, Dr. Tsai wrote 1,018 Medicare Part D claims for 270 patients. 78% of them were for generic drugs. CMS names the drug for 753 of them, across 26 drugs with 11 or more claims each, at $1,281,959 in total drug cost. In 2023, CMS named 770 claims across 28 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Tsai for performance year 2024, reported as part of a group. Dr. Tsai accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tsai as offering telehealth.

Dmand AI links 2 papers to Dr. Tsai, published from 2005 to 2025. Dr. Tsai's most frequent co-authors are Constantin Dasanu, MD, PhD and Henry K. Tsai, MD.

Dmand AI links Dr. Tsai to 10 clinical trials, 7 of them phase 3 studies. 8 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Carcinoma, Renal Cell. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 221 general payments to Dr. Tsai from 29 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 79% of the total. Merck Sharp & Dohme Corporation paid the most, $74,356.

Dr. Tsai graduated from Wayne State University School Of Medicine in 2001.

Dr. Tsai is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.